On June 15, 2025, Prothena Corp announced that its partner Roche is advancing prasinezumab into Phase III development for early-stage Parkinson’s disease, indicating progress in their collaboration.
AI Assistant
PROTHENA CORP PUBLIC LTD CO
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.